Indoco Remedies Limited has informed the Exchange regarding a press release dated September 19, 2025, titled "USFDA successfully completes inspection at Indoco s API manufacturing facility at Patalganga with zero observations".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies has announced that the USFDA (US drug regulator) has successfully completed an inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility at Patalganga with zero observations. Zero observations means the regulator found no deficiencies or violations during the inspection, and no Form 483 was issued. This indicates the facility meets US quality and manufacturing standards. The outcome removes any regulatory overhang on this particular facility and supports the company's credibility for supplying APIs to the US market.
Positive for shareholders — a clean USFDA inspection strengthens Indoco's standing in the highly lucrative US market, boosts export potential, and removes near-term compliance risk. Typically such news acts as a short-term positive catalyst for the stock.